RT Journal Article
SR Electronic
T1 Antibody therapy reverses biological signatures of COVID-19 progression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.21.21268197
DO 10.1101/2021.12.21.21268197
A1 Maher, M. Cyrus
A1 Soriaga, Leah B.
A1 Gupta, Anil
A1 di Iulio, Julia
A1 Ledoux, Sarah
A1 Smithey, Megan J.
A1 Cathcart, Andrea L.
A1 McKusick, Kathleen
A1 Sun, David
A1 Aldinger, Melissa
A1 Alexander, Elizabeth
A1 Purcell, Lisa
A1 Ding, Xiao
A1 Peppercorn, Amanda
A1 Austin, Daren
A1 Mogalian, Erik
A1 Yeh, Wendy W.
A1 Shapiro, Adrienne E.
A1 Corti, Davide
A1 Virgin, Herbert W.
A1 Pang, Phillip S.
A1 Telenti, Amalio
YR 2021
UL http://medrxiv.org/content/early/2021/12/27/2021.12.21.21268197.abstract
AB Understanding who is at risk of progression to severe COVID-19 is key to effective treatment. We studied correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the treatment of SARS-CoV-2 infection. Several laboratory parameters identified study participants at greater risk of severe disease, including a high neutrophil-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test and whole blood transcriptome profiles. Sotrovimab treatment in these groups was associated with normalization of NLR and the transcriptomic profile, and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provided the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identified a 10-gene signature with similar predictive accuracy. In summary, we identified markers of risk for disease progression and demonstrated that normalization of these parameters occurs with antibody treatment of established infection.Competing Interest StatementThis study was sponsored by Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline. M.C.M., L.B.S., J.diI., S.L., M.J.S., A.A., K.M., D.S., M.A., E.A., L.P., X.D., E.M., W.Y., D.C., H.W.V., P.S.P. and A.T. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. D.A. and A.P are employees of and hold shares in GlaxoSmithKline.Clinical TrialNCT04545060Funding StatementThis study was sponsored by Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the following ethics review boards: Research Ethical Committee of the Universidade De Passo Fundo/Office Of The Assistant Dean Of Research And Graduate Studies, Brazil (454545/249305), Research Ethical Committee of the Liga Norte Riograndense Contra O Cancer, Brazil (356987/249067), Comite de Etica em Pesquisa do Hospital Leforte, Brazil (454407/249306; 454407/249306), Research ethical Committee of the Hospital de Clinicas de Porto Alegre of the Federal University of Rio Grande do Sul, Brazil (412641/249076), Research Ethical Committee of the Brotherhood of the Holy House of Mercy of Porto Alegre, Brazil (452132/249278), Advarra, Canada (125285/249219; 233252/249074), Comite Nacional Transitorio de Etica en Investigacion para la evaluacion y supervision eticas de los Ensayos Clinicos de la enfermedad COVID-19 (CNTEI COVID-19), Peru (453319/249281), CEIm Corporacio Sanitaria Parc Tauli Parque del Tauli, Spain (466003/249291; 010074/249923; 230601/249242), Advarra, United States (316647/249611; 393090/249560; 320687/249555; 427380/249631; 093073/249546; 449583/248364; 009334/249320; 021490/248894; 457707/249681; 076115/248362; 457712/249682; 354044/249803; 171466/248900; 458530/249910; 457765/249683; 408728/249251; 458692/249844; 176292/249239; 006879/248345; 347052/249553; 455576/249387; 455582/249389; 456034/249493; 053521/249195; 455575/249386; 028996/249554; 458529/249909; 370717/249241; 331745/249072; 453800/249220; 459369/249998; 429263/248346; 455578/249390; 457328/249637; 259973/249632; 023446/249253; 457766/249684; 456703/249634; 014897/248899; 306670/249073; 306670/249073; 007907/250048; 373940/248347; 419336/249556; 455826/249420. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability is subject to the clinical trial charter